Tae-gyun Woo
Busan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
Journal: Communications biology
Published: June 27, 2026
Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.
Journal: International journal of molecular sciences
Published: January 09, 2026
Progerin expression in humans: Implications for natural ageing.
Journal: Mechanisms of ageing and development
Published: December 09, 2025
Therapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor.
Journal: Neuro-oncology
Published: December 28, 2024
Inhibition of SOD1 trimerization is a novel drug target for ALS disease.
Journal: Translational neurodegeneration
Published: November 11, 2024
The therapeutic effect of DX2 inhibition in nicotine-induced lung cancer progression.
Journal: Molecular therapy. Oncology
Published: June 03, 2024
NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.
Journal: International journal of molecular sciences
Published: May 04, 2024
Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS.
Journal: Cells
Published: August 08, 2023
Structural analysis of the overoxidized Cu/Zn-superoxide dismutase in ROS-induced ALS filament formation.
Journal: Communications biology
Published: March 18, 2022
Splicing Variants, Protein-Protein Interactions, and Drug Targeting in Hutchinson-Gilford Progeria Syndrome and Small Cell Lung Cancer.
Journal: Genes
Published: December 11, 2021
Author Correction: Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.
Journal: Scientific reports
Published: September 02, 2021
Last Updated: 09/26/2026